|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HIF-1alpha, which is induced by hypoxia, is the most important regulatory factor of many specific genes that can influence the biological features of tumors.
|
20003295 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HIF1-positive and HIF1-negative glioblastoma cells compete in vitro but cooperate in tumor growth in vivo.
|
20198320 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HIF-1alpha expression is associated with tumor resistance to cytotoxic therapy and inferior patient outcomes.
|
20587661 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HIF-1α (hypoxia-inducible factor 1 alpha) is believed to promote oesophageal squamous tumour growth.
|
20977428 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HIF1 regulates transcription of genes relevant for vascularization, glucose transport and glycolysis, processes that facilitate tumor growth.
|
21404119 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HIF-1α expression was found in 15% of IDH-mutated compared to 7.7% of IDH-nonmutated tumors (P = 0.954).
|
21643985 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HIF-1α mediates tumor hypoxia to confer a perpetual mesenchymal phenotype for malignant progression.
|
21693763 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HIF-1α protein expression was significantly higher in the tumor cell population than in adjacent normal cells in both subgroups (P = 0.009 for TNBC and P = 0.028 for TN-ACC, respectively), but there was no significant difference between the two tumor groups.
|
21892750 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Hypoxia-inducible factor-1α (HIF-1α) and its downstream target, vascular endothelial growth factor (VEGF), play a critical role in tumour angiogenesis and represent an attractive chemotherapeutic target.
|
22170854 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HIF-1 activity in tumors depends on availability of the HIF-1α subunit, the levels of which increase under hypoxic conditions and through activation of oncogenes and/or inactivation of tumor suppressor genes.
|
22305612 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HIF-1α and pVHL expression were studied using immunohistochemical (IHC) methods in the tumor and adjacent benign tissue.
|
22820662 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Hypoxia-inducible factor-1α (HIF-1α) is an attractive therapeutic target because it is a key transcription factor in tumor development and only accumulates in hypoxic tumors.
|
22924580 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HIF-1α is the key mediator of the cellular response to oxygen deprivation and induces the expression of genes involved in survival and angiogenesis within solid hypoxic tumors.
|
23023398 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HIF-1α inhibition caused a dramatic reduction in the weight and volume of the tumor burden in both mouse models.
|
23344526 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HIF-1α regulated genes are mainly responsible for tumour resistance to radiation- and chemo-therapy.
|
23706268 |
2013 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
HIF-1α G1790A polymorphism was found to be associated with increased risk of larger tumor size (G/G + G/A vs. A/A: OR = 1.64, 95% CI = 1.04-2.58) and borderline significant risk of lymph node metastasis (G/G + G/A vs. A/A: OR = 1.33, 95% CI = 1.00-1.78).
|
23857282 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Hypoxia-inducible factor 1α (HIF-1α) and p53 are pivotal regulators of tumor growth.
|
23880760 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.
|
23999440 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HIF-1α and NF-κB are two transcription factors very frequently activated in tumors and involved in tumor growth, progression and resistance to chemotherapy.
|
24286852 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HIF-1α may have a regulatory effect on MDR1 expression in refractory epilepsy, which is probably consistent with MDR mechanism in tumor.
|
24590840 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Hypoxia inducible factor-1 alpha (HIF-1α) is the key regulator of cellular responses to hypoxia and plays a central role in tumour growth.
|
25520138 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Hypoxia-inducible factor 1α (HIF-1α) activity is one of the major players in hypoxia-mediated glioma progression and resistance to therapies, and therefore the focus of this study was the evaluation of HIF-1α modulation in relation to tumour response with the purpose of identifying imaging biomarkers able to document tumour response to treatment in a murine glioma model.
|
25813354 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HIF1α degradation favors ccRCC proliferation, in line with the previously recognized tumor suppressor capability of HIF1α.
|
25915846 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Hypoxia inducible factor-1α (HIF-1α), induces cytokines such as CXCL8 and tumor dissemination, chemo- and radio-resistance.
|
26078356 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HIF-1α is a very important molecule promoting neoplasm aggressiveness, metastasis through the induction of the epithelial to mesenchymal transition (EMT).
|
26094772 |
2015 |